Disease: CRISPR SARS-CoV-2 Diagnostic kit Coronavirus (COVID-19) Disease

Disease info:

COVID-19 is the infectious disease caused by the coronavirus, SARS-CoV-2, which is a respiratory pathogen.

The most common symptoms of COVID-19 are: fever, dry cough, fatigue

Other symptoms that are less common and may affect some patients include: loss of taste or smell, nasal congestion, conjunctivitis (also known as red eyes), sore throat, headache, muscle or joint pain, different types of skin rash, nausea or vomiting, diarrhea, chills or dizziness.

Most people (about 80%) recover from the disease without needing hospital treatment. About 20% of those who get COVID-19 become seriously ill and require oxygen, with 5% becoming critically ill and needing intensive care.

Complications leading to death may include respiratory failure, acute respiratory distress syndrome (ARDS), sepsis and septic shock, thromboembolism, and/or multiorgan failure, including injury of the heart, liver or kidneys.

In rare situations, children can develop a severe inflammatory syndrome a few weeks after infection.

In most situations, a molecular test is used to detect SARS-CoV-2 and confirm COVID-19. Polymerase chain reaction (PCR) is the most commonly used molecular test. Samples are collected from the nose and/or throat with a swab. Molecular tests detect virus in the sample by amplifying viral genetic material to detectable levels. For this reason, a molecular test is used to confirm an active infection, usually within a few days of exposure and around the time that symptoms may begin. 

Rapid tests (sometimes known as a rapid diagnostic test – RDT) detect viral proteins (known as antigens). Samples are collected from the nose and/or throat with a swab. These tests are cheaper than PCR and will offer results more quickly, although they are generally less accurate. 

Due to the ongoing pandemic, frequency data of COVID-19 cases are monitored via the WHO COVID-19 Dashboard. Globally, as of 10:33am CEST, 17 October 2020, there have been 39,023,292 confirmed cases of COVID-19, including 1,099,586 deaths.
Official title:
Study start:
CRISPR-Cas13 SARS-CoV-2 kit
Coronavirus disease (COVID-19)
Target gene:
Nucleoprotein (N), Open Reading Frame 1-ab (ORF1ab)
Safety updates:



The Sherlock CRISPR SARS-CoV-2 kit has been designed to detect fragments of the Open Reading Frame (ORF1ab, “O”) gene and the Nucleoprotein (“N”) gene of SARS-CoV-2. An included third target is the human RNase P POP7 gene (“RP”) which serves as a control for the extraction of the clinical sample in the absence of a positive SARS-CoV-2 result. A dedicated instrument platform (e.g., thermal cycler) is not required. Amplification can be performed using a heat block, and CRISPR complex activation and reporter cleavage can be run in a standard microplate reader capable of fluorescence detection. The entire reaction from RT-LAMP amplification to CRISPR-based detection of the target analytes can be performed in approximately one hour.

The Sherlock CRISPR SARS-CoV-2 kit comprises two steps. Step one is a reverse transcriptase loop-mediated amplification (RT-LAMP) where targeted SARS-CoV-2 genomic RNA is reverse transcribed to DNA, and this DNA is amplified by a strand-displacing DNA polymerase. Step two is the transcription of the amplified DNA to activate the collateral cleavage activity of a CRISPR complex programmed to the target RNA sequence. This collateral activity results in cleavage of nucleic acid reporters, resulting in a fluorescent readout detected by a plate reader.

Positive Control: Quantified extracted SARS-CoV-2 genomic RNA

Negative Control: Molecular grade, nuclease-free water

The CRISPR SARS-CoV-2 kit is designed to detect RNA from upper respiratory specimens (such as nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, nasopharyngeal wash/aspirate or nasal aspirate) and bronchoalveolar lavage specimens from patients suspected of COVID-19 by their healthcare provider.

Last updated: Oct. 28, 2021
Search CRISPR Medicine